Genic (Korea) Today
| 123330 Stock | KRW 19,860 570.00 2.95% |
Performance8 of 100
| Odds Of DistressLess than 28
|
Genic is trading at 19860.00 as of the 19th of December 2024, a 2.95 percent increase since the beginning of the trading day. The stock's open price was 19290.0. Genic has about a 28 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 25th of December 2023 and ending today, the 19th of December 2024. Click here to learn more.
Genic Co., Ltd. researches, develops, manufactures, and sells hydrogel mask packs in South Korea and internationally. The company was founded in 2001 and is based in Seongnam-si, South Korea. Genic is traded on Korean Securities Dealers Automated Quotations in South Korea. The company has 6.85 M outstanding shares. More on Genic Co
Moving against Genic Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Genic Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Genic's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Genic or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Cheol Park |
| Business Concentration | Consumer Staples, Personal Products (View all Sectors) |
Genic Co (123330) is traded on KOSDAQ in Korea and employs 204 people. The company currently falls under 'Large-Cap' category with a current market capitalization of 34.45 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Genic's market, we take the total number of its shares issued and multiply it by Genic's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Genic has 6.85 M outstanding shares.
Genic Co has accumulated about 17.19 B in cash with 3.32 B of positive cash flow from operations.
Check Genic Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Genic is W34.45 Billion. Genic secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Genic Ownership Details
Genic Risk Profiles
Although Genic's alpha and beta are two of the key measurements used to evaluate Genic's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 5.13 | |||
| Semi Deviation | 3.75 | |||
| Standard Deviation | 7.13 | |||
| Variance | 50.85 |
Genic Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Genic without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Insider Screener Now
Insider ScreenerFind insiders across different sectors to evaluate their impact on performance |
| All Next | Launch Module |
Genic Corporate Management
Elected by the shareholders, the Genic's board of directors comprises two types of representatives: Genic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genic. The board's role is to monitor Genic's management team and ensure that shareholders' interests are well served. Genic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genic's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeong Han | Internal Auditor | Profile | |
| Hyunho Yoo | Chief Officer | Profile | |
| Kim Cheol | Managing Director | Profile | |
| SungEun Kim | Managing Director | Profile | |
| KangDon Oh | Managing Director | Profile |
Other Information on Investing in Genic Stock
Genic financial ratios help investors to determine whether Genic Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Genic with respect to the benefits of owning Genic security.